Navigation Links
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
Date:11/13/2009

PLYMOUTH, Mich., Nov. 13 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins. The single escalating dose study in healthy volunteers will be the first clinical study conducted by Esperion since the re-establishment of the company in May 2008.

ETC-1002 is being developed to treat dyslipidemia, an early-stage risk factor of coronary artery disease and associated metabolic syndromes. The compound targets lipid metabolism in two ways: first, by inhibiting fatty acid and cholesterol synthesis; and second, by enhancing oxidation of fatty acids. ETC-1002 therefore has the potential to lower LDL-C and triglycerides and also to increase HDL-C.

"Our pre-clinical research related to ETC-1002 has been very promising, and we are pleased to advance this new product candidate to clinical development. ETC-1002 is the flagship product of our dyslipidemia program, and it will also be the first product in our pipeline to reach clinical-stage development," said Roger Newton, PhD, FAHA, president and CEO of Esperion Therapeutics. "Just over a year and a half following the re-establishment of Esperion, we continue to progress toward our goal of bringing breakthrough cardiovascular and metabolic disease therapies to market."

Cardio-metabolic diseases are the leading cause of morbidity and mortality among men and women in industrialized countries around the world.

"We are very well positioned to move ahead with the development effort for ETC-1002 as we also advance our other promising pre-clinical research programs in both acute and chronic therapies to treat cardiovascular and metabolic disorders," Mr.
'/>"/>

SOURCE Esperion Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
2. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
3. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
4. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
5. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
6. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
7. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... RESEARCH TRIANGLE PARK, N.C. , Sept. 17, 2014 ... speakers and presentation topics that will be featured at ... Center,s Hamner Conference Center on December 3 and 4, ... biotechnology managers are invited to hear the following: ... , PhD UC San Diego Skaggs School ...
(Date:9/17/2014)... 2014 JH Technologies announces ... in Irvine. JH Technologies, a leader in sales ... announced an expanded partnership with Leica Microsystems into the ... image analysis solutions will be featured at the grand ... new showroom facility is located within the JH Technologies ...
(Date:9/17/2014)... 17, 2014 Hussey Copper , a ... antimicrobial copper, announces Gilmour Academy Ice Arena,s conversion ... EPA-registered antimicrobial solid touch surface to help protect against ... priced surface that kills greater than 99.9% of MRSA, ... 1 , ...
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
Breaking Biology Technology:In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... is the 11th in a series of articles on developing ... , Madison, Wis. - You've started your ... perhaps through investors. If you still need additional funding, what ... are basic financial principles to consider. , ,Most of ...
... Web-software services provider Zywave Inc. recently announced it ... being constructed in the Milwaukee County Research Park . ... real estate development circles, but the news is more than ... playing out, and an example of how a powerful business ...
... surging trend that has taken corporate boardrooms by ... pressure from myriad interest groups around the world ... and reporting. In 2005, according to Professor Michael ... CSR-related shareholder resolutions were filed on issues ranging ...
Cached Biology Technology:Early Stage: Step 11 - Other forms of finance 2Early Stage: Step 11 - Other forms of finance 3Early Stage: Step 11 - Other forms of finance 4Corporate venturing can nurture software success 2Corporate venturing can nurture software success 3Corporate venturing can nurture software success 4Corporate venturing can nurture software success 5Corporate venturing can nurture software success 6Corporate Social Responsibility - Burden, sham, or golden opportunity? 2Corporate Social Responsibility - Burden, sham, or golden opportunity? 3Corporate Social Responsibility - Burden, sham, or golden opportunity? 4Corporate Social Responsibility - Burden, sham, or golden opportunity? 5Corporate Social Responsibility - Burden, sham, or golden opportunity? 6Corporate Social Responsibility - Burden, sham, or golden opportunity? 7
(Date:9/17/2014)... Arts and Humanities has received a $260,000 grant from ... "The Boundaries of the Human in the Age of ... wide-ranging series of events aimed at exploring two compelling ... and researchers who are exploring the boundaries of our ... and the other involves the increasingly influential hypothesis that ...
(Date:9/17/2014)... "Nature has developed, very cleverly, some lessons on how ... design," said Joseph Shaw, director of the Optical Technology ... and structures at the nanoscale, we,ll discover them." , ... in August during a conference called "The Nature of ... Liang of the University of Arizona College of Optical ...
(Date:9/17/2014)... researchers have obtained the first partial genome sequence of ... found at the site of the Montsoriu Castle in ... is closely related to today,s Iberian pig. Researchers also ... modern Iberian pigs. , The study, published in ... pig species, and particularly on that of the Iberian ...
Breaking Biology News(10 mins):Mellon Foundation awards grant for major project in the humanities and sciences 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Iberian pig genome remains unchanged after 5 centuries 2
... This release is available in Spanish . The ... Hesprides, will set out from Cdiz on Tuesday 15th November. The ... Council (CSIC) which aims to gauge the impact of global change ... off, which will take place at 11 a.m. on the east ...
... health professionals search for ways to combat the rise in ... own eating habits and whether she views her child ... whether her child consumes enough fruits and vegetables. ... College of Nursing looked at nearly 400 low-income women (black ...
... State University biologist Kenro Kusumi,s life in 1980 when, as ... his field notebook that he had found an Anolis egg ... with other memorabilia that document the influence that both his ... current pursuits in developmental biology. One such souvenir is a ...
Cached Biology News:Malaspina 2010, the biggest ever expedition on global change, sets sail 2Malaspina 2010, the biggest ever expedition on global change, sets sail 3Malaspina 2010, the biggest ever expedition on global change, sets sail 4Mothers' diets have biggest influence on children eating healthy 21 tale told is 2 tails gained 21 tale told is 2 tails gained 31 tale told is 2 tails gained 4
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Biology Products: